Trial Profile
Phase 1B Study of buparlisib with Bortezomib in Defined Genetic Subgroups of Patients with Relapsed or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 May 2022
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Buparlisib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms Bubble
- 28 Jul 2020 Planned End Date changed from 1 Jun 2019 to 9 Apr 2021.
- 28 Jul 2020 Status changed from recruiting to active, no longer recruiting.
- 04 Apr 2016 Status changed from not yet recruiting to recruiting, as reported by ISRCTN: Current Controlled Trials.